Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatranPaul A. Reilly, Charles V. Pollack, Richard A. Bernstein et al.|Thrombosis and Haemostasis|2015Cited by 154
Noninvasive echo-Doppler duplex measurements of common femoral artery blood flow variables during supine exercise and post-occlusive reactive hyperemia.Melissa Sutton, Paul A. Reilly, Elaine C. Johnson et al.|PubMed|1982Cited by 5